Key result
Exogenous creatine phosphate infusion after PCI significantly reduced the incidence of CK-MB elevation of 1 to 3 times compared to conventional therapy (8.0% vs 19.0%).
Why the study?
Does exogenous creatine phosphate reduce myocardial injury in patients after percutaneous coronary intervention?
Does exogenous creatine phosphate reduce myocardial injury in patients after percutaneous coronary intervention?
Absolute Event Rate: 8% vs 19%
A 3-day intravenous infusion of exogenous creatine phosphate after PCI significantly reduced the proportion of patients experiencing marked elevations in cardiac biomarkers.
Post-PCI CP linked to higher injury markers; hypothesis-generating and requires RCTs before any practice consideration.
OBJECTIVE: To evaluate the effect of exogenous creatine phosphate (CP) on myocardial injury after percutaneous coronary intervention (PCI). METHOD: Four hundred patients were divided to receive conventional therapy (control group) or 3-day intravenous infusion of CP after PCI (CP group). Levels of creatine kinase MB (CK-MB) and troponin I (TnI) were measured before and on postprocedural day 3. RESULTS: Postprocedural CK-MB and TnI in the CP group were significantly increased compared to the control group. In the CP group, 8.0% and 5.0% of patients had an increase in CK-MB 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (19.0% and 9.0%, respectively); 12.0% and 10.0% of patients had an increase in TnI 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (21.0% and 18.0%, respectively). CONCLUSION: Exogenous CP was helpful to reduce myocardial injury after PCI.
No takes yet. Share an insight, caveat, or question.
Xubo et al. (2013) studied Myocardial injury after percutaneous coronary intervention (n=400). Exogenous creatine phosphate vs. Conventional therapy was evaluated on Increase in CK-MB 1 to 3 times. Exogenous creatine phosphate infusion after PCI significantly reduced the incidence of CK-MB elevation of 1 to 3 times compared to conventional therapy (8.0% vs 19.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: